IRIS
BERARDI, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.752
EU - Europa 6.073
AS - Asia 2.179
AF - Africa 293
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 7
SA - Sud America 5
Totale 24.323
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.739
UA - Ucraina 1.309
IT - Italia 1.082
IE - Irlanda 1.051
SE - Svezia 792
SG - Singapore 719
DE - Germania 661
CN - Cina 570
TR - Turchia 488
DK - Danimarca 451
FI - Finlandia 318
KR - Corea 254
GB - Regno Unito 251
CI - Costa d'Avorio 218
IN - India 123
MA - Marocco 68
BE - Belgio 61
FR - Francia 30
RO - Romania 18
EU - Europa 14
CA - Canada 12
JP - Giappone 12
NL - Olanda 10
RU - Federazione Russa 10
AT - Austria 7
HK - Hong Kong 5
NZ - Nuova Zelanda 5
GR - Grecia 4
BI - Burundi 3
CH - Svizzera 3
DZ - Algeria 3
HR - Croazia 3
PL - Polonia 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CO - Colombia 2
ES - Italia 2
AZ - Azerbaigian 1
BT - Bhutan 1
CL - Cile 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
IL - Israele 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
PE - Perù 1
PR - Porto Rico 1
TH - Thailandia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 24.323
Salva come PNG Salva come JPEG
Città #
Chandler 2.049
Jacksonville 1.507
Fairfield 1.491
Des Moines 1.152
Ashburn 1.090
Dublin 1.044
Boardman 963
Wilmington 725
Woodbridge 665
Seattle 626
Houston 577
New York 501
Ann Arbor 496
Cambridge 482
Lawrence 389
Princeton 389
San Mateo 365
Singapore 244
Centro 223
Abidjan 218
San Diego 185
Turin 108
Beijing 104
Pune 96
Washington 95
Helsinki 86
London 77
Los Angeles 70
Dallas 62
Brussels 60
Ancona 49
Shanghai 47
Guangzhou 46
Marche 41
Milan 41
Falls Church 40
Norwalk 37
Tolentino 27
Wuhan 27
Kilburn 26
Prescot 21
Redmond 21
Porto 19
Jiaxing 18
Izmir 17
Rome 16
Chiaravalle 15
Wuxi 15
Shenzhen 13
Visakhapatnam 13
Brasov 12
Hounslow 12
Yiwu 12
Seoul 11
Santa Clara 10
Xi'an 10
Chiswick 9
Ningbo 9
Squinzano 9
Chengdu 8
Cantu 7
Hangzhou 7
New Bedfont 7
Zhengzhou 7
Civitanova Marche 6
Fayetteville 6
Jinhua 6
Torre Del Greco 6
Vienna 6
Acton 5
Amsterdam 5
Auburn Hills 5
Cascina 5
Cupra Marittima 5
Nürnberg 5
Ottawa 5
Quanzhou 5
Redwood City 5
Saint Louis 5
Arnold 4
Bologna 4
Falconara Marittima 4
Fermignano 4
Florence 4
Gurugram 4
Islington 4
Jesi 4
Nanjing 4
Scafati 4
Southwark 4
Venice 4
Wandsworth 4
West Jordan 4
Acerra 3
Andover 3
Ascoli Piceno 3
Auckland 3
Bari 3
Camerino 3
Castelraimondo 3
Totale 16.975
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 188
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy 172
Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature 162
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 160
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 131
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 129
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 121
Squamous cell carcinoma of the lung: clinical criteria for treatment strategy 117
Are liver nested stromal epithelial tumors always low aggressive? 115
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 114
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 112
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 110
Thymic Malignancies in the targeted terapies era 106
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 105
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 105
Metabolic phenotype of bladder cancer 105
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 104
Rossana Berardi, Mariangela Torniai, Agnese Savini, Silvia Rinaldi, Stefano Cascinu. Gastro-entero-pancreatic neuroendocrine tumors: is now time for a new approach? 103
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 103
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 102
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 101
Role of DCE-MR in predicting breast cancer subtypes. 100
Optimal management of resected gastric cancer 100
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study 100
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 99
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 99
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 98
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 96
Severe prognosis of signet-ring cell adenocarcinoma occurring in meckel’s diverticulum 94
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 94
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 93
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 92
Progress of molecular targeted therapies for advanced renal cell carcinoma. 92
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 91
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 91
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 91
Pancreatic cancer: progress in cancer therapy. 90
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 89
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions 89
Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. 88
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 88
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 88
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 88
Adjuvant treatment after surgical resection 88
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 87
Electrolyte disorders in cancer patients: a systematic review 87
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 87
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 86
Lynphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. 86
Contrasting Digital Fake News in Health: an Interdisciplinary Approach 86
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 85
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 84
Gender differences and outcome of melanoma patients 84
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 84
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 84
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 84
5-Fluorouracil pharmacogenomics: still rocking after all these years? 83
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 83
Hyponatremia in cancer patients: Time for a new approach 83
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma 83
Managing hyponatremia in lung cancer: latest evidence and clinical implications 83
The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer 83
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 82
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 82
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 82
New target therapies in advanced pancreatic cancer. 81
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 81
Evaluation of Multifocality and multicentricity with Breast Magnetic Resonance Imaging in each breast cancer subtype 81
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 81
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 81
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 81
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 80
Chromium Exposure and Germinal Embryonal Carcinoma: first Two Cases and Review of the Literature 80
Medical treatment for cholangiocarcinoma 80
Social distress among Medical Oncologists and other Health Care Professionals during the first wave of COVID-19 pandemic in Italy 80
Extended efficacy and safety Denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. 80
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer 80
Randomized active-controlled phase 2 study of Denosumab efficacy and safety in patients with breast cancer-related bone metastases. 79
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 79
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 78
Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer 78
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 78
Gender Differences and Outcomes in Melanoma Patients 78
Benefits and limitations of a multidisciplinary approach in cancer patient management 78
Paraneoplastic Syndromes. 77
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 77
A cost-benefit analysis of chemotherapy for gastric cancer. 76
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 76
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report 75
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 75
Contrasting Fake News in Oncology: The First Declaration of Good Communication 75
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 75
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? 74
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 74
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma 74
Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer. 73
Resected biliary tract cancers: A novel clinical-pathological score correlates with global outcome 73
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 73
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 73
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 73
Totale 9.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.193
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.738 0 7 250 19 273 3 265 24 269 91 96 441
2020/20215.907 292 547 796 342 738 391 506 437 490 454 569 345
2021/20223.059 169 642 78 98 42 224 125 209 303 208 329 632
2022/20236.361 520 648 404 531 338 1.619 2 325 1.359 58 412 145
2023/20243.667 581 83 234 409 575 879 52 132 10 132 51 529
2024/20251.532 855 677 0 0 0 0 0 0 0 0 0 0
Totale 25.109